Literature DB >> 16939768

Infliximab for Kawasaki syndrome.

Tsutomu Saji, Yasushi Kemmotsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16939768     DOI： 10.1016/j.jpeds.2005.07.039

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  8 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Jane C Burns; Brookie M Best; Asuncion Mejias; Lynn Mahony; David E Fixler; Hasan S Jafri; Marian E Melish; Mary Anne Jackson; Basim I Asmar; David J Lang; James D Connor; Edmund V Capparelli; Monica L Keen; Khalid Mamun; Gregory F Keenan; Octavio Ramilo
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

Review 3.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

4.  Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.

Authors:  Eisuke Suganuma; Fumio Niimura; Shinichi Matsuda; Toshiko Ukawa; Hideaki Nakamura; Kaori Sekine; Masahiko Kato; Yuji Aiba; Yasuhiro Koga; Kuniyoshi Hayashi; Osamu Takahashi; Hiroyuki Mochizuki
Journal:  Pediatr Res       Date:  2016-12-20       Impact factor: 3.756

5.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

6.  A novel mouse model of coronary stenosis mimicking Kawasaki disease induced by Lactobacillus casei cell wall extract.

Authors:  Eisuke Suganuma; Satoshi Sato; Satoko Honda; Atsuko Nakazawa
Journal:  Exp Anim       Date:  2020-01-13

Review 7.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

8.  Kawasaki disease patients homozygous for the rs12252-C variant of interferon-induced transmembrane protein-3 are significantly more likely to develop coronary artery lesions.

Authors:  Neil E Bowles; Cammon B Arrington; Keiichi Hirono; Tsuneyuki Nakamura; Long Ngo; Yin Shen Wee; Fukiko Ichida; John H Weis
Journal:  Mol Genet Genomic Med       Date:  2014-05-14       Impact factor: 2.183
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.